Valuation: Axsome Therapeutics, Inc.

Market Cap 12.33B 10.8B 10.03B 9.22B 17.37B 1,190B 17.62B 119B 46.77B 582B 46.29B 45.29B 2,011B P/E 2026 *
-116x
P/E 2027 * 43.2x
Enterprise Value 12.22B 10.71B 9.94B 9.13B 17.21B 1,179B 17.46B 118B 46.35B 577B 45.87B 44.88B 1,993B EV / Sales 2026 *
12.5x
EV / Sales 2027 * 7.48x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.13%
1 week+0.88%
Current month-2.10%
1 month-3.32%
3 months+28.54%
6 months+28.15%
Current year+31.20%
1 week 221.21
Extreme 221.21
240.73
1 month 221.21
Extreme 221.21
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+1.13%+0.88%+133.66%+218.90% 12.33B
-3.56%-2.00%+16.09%-11.36% 66.25B
-0.78%+1.56%+35.73%+196.49% 52.86B
-1.65%+37.20%+37.20%+37.20% 43.01B
-1.86%-5.08%-56.40%-56.53% 39.52B
-2.67%+0.25%+54.67%-28.55% 29.19B
-2.67%-14.95%+77.42%-54.07% 23.04B
-1.36%+0.61%+68.06%+80.50% 23.13B
-1.14%-3.13%+3.69%+174.85% 20.48B
-1.27%+1.58%+71.18%+122.26% 16.6B
Average -1.58%-1.77%+44.13%+67.97% 32.64B
Weighted average by Cap. -1.90%-1.44%+31.20%+52.36%

Financials

2026 *2027 *
Net sales 979M 858M 796M 732M 1.38B 94.46B 1.4B 9.49B 3.71B 46.22B 3.67B 3.6B 160B 1.6B 1.4B 1.3B 1.19B 2.25B 154B 2.28B 15.47B 6.05B 75.37B 5.99B 5.86B 260B
Net income -107M -94.01M -87.28M -80.2M -151M -10.35B -153M -1.04B -407M -5.07B -403M -394M -17.5B 309M 271M 251M 231M 435M 29.83B 442M 3B 1.17B 14.6B 1.16B 1.14B 50.42B
Net Debt -111M -96.99M -90.04M -82.74M -156M -10.68B -158M -1.07B -420M -5.23B -416M -407M -18.06B -394M -345M -320M -294M -555M -38B -563M -3.82B -1.49B -18.59B -1.48B -1.45B -64.23B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-22 $239.62 +1.13% 648,276
26-07-21 $236.95 +6.91% 993,638
26-07-20 $221.64 -3.63% 776,410
26-07-17 $230.00 -2.97% 878,315
26-07-16 $237.04 -0.21% 639,658
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
239.62USD
Average target price
282.51USD
Spread / Average Target
+17.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock